Clinical trial
Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)
NCT00396812 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00396812 |
|---|---|
| Title | Rituximab for the Treatment of Early Rheumatoid Arthritis (RA) |
| Official title | An Open Label, Single Arm, Single Center, Phase I/II Trial of Rituximab (a Monoclonal Antibody to CD20) for the Treatment of Early Rheumatoid Arthritis |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Autoimmunity Centers of Excellence |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 4 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Nov 8, 2006 |
| Last update posted | Feb 12, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: